uterine cervical neoplasms

Uterine Cervical Neoplasms

human papillomavirus

PMID (1):

41730538

MeSH

Vulvar cancer

Cervix Uteri

Lichen Sclerosus et Atrophicus

A concise list of important things to know about vulvar cancer. James W. Mold, MD, MPH

View

Vulvar cancer is an underrecognized gynecologic malignant disease. The incidence of vulvar cancer is 2.3 per 100 000 people in Canada, and is increasing with the rising prevalence of human papillomavirus (HPV). More than 90% of vulvar cancers are squamous cell carcinomas (SCC), mostly diagnosed after age 65 years. Vulvar SCC mimics nonspecific inflammation, which often delays diagnosis. Risk factors include advanced age, HPV infection, lichen sclerosis, smoking, immunodeficiency, and pelvic radiation

Author/s:

Jennifer Davis, Jacob McGee, Anjali Kulkarni

New Cervical Cancer Screening Guidelines From the US Department of Health and Human Services: Strengthening Women’s Preventive Health

Megan George — Tue, 06 Jan 2026 14:29:39 +0000

Date Added:

January 6, 2026

Journal/Publication:

JAMA

Publication Date:

January 5, 2026

URL:

New Cervical Cancer Screening Guidelines From the US Department of Health and Human Services: Strengthening Women’s Preventive Health

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2025.26456

Keywords

cervical cancer

Cancer Screeing

PMID (1):

41489823

MeSH

Papanicolaou Test

Uterine Cervical Dysplasia

Human Papillomavirus and Cancer

Updated HRSA (2026) guidelines for cervical cancer screening. James W. Mold, MD, MPH

View

Cervical cancer screening is one of the most significant public health accomplishments of the 20th century. Over the last 50 years, incidence and mortality rates from cervical cancer in the US have decreased by more than 50%1 because of widespread use of the Papanicolaou test and later adoption of high-risk human papillomavirus (hrHPV) testing.

Regular screening is critical in detecting disease because women with precancerous cervical intraepithelial neoplasia or early-stage cervical cancer are often asymptomatic. When detected early, 5-year cervical cancer survival is higher than 90%.1 Yet more than half of all cervical cancer diagnoses are made beyond an early stage; 37% when cancer has spread regionally to local lymph nodes and 15% when there are distant cancer metastases. Five-year survival is just 20% for women diagnosed with metastatic disease.1

Cervical cytology (Papanicolaou test) and hrHPV tests are highly effective in detecting early, more treatable disease; however, these modalities are only beneficial for women who undergo recommended screening. Unfortunately, about half of all women diagnosed with cervical cancer have never been screened or are not up-to-date on screening,2 and these women are more likely to present with regional or distant metastatic disease. Overall, approximately 1 in 4 women in the US are not up-to-date on cervical cancer screening.3 Women living in poverty or having fewer years of formal education have even lower screening rates. The direct link between screening and survival illustrates a clear and urgent need to improve cervical cancer screening rates in the US; new self-collection options approved by the US Food and Drug Administration (FDA) provide an opportunity to do so.

Author/s:

Brian Christine, Margaret Bush, Anita Thurakal, Ann M Sheehy

Human Papillomavirus and Cancer

Megan George — Thu, 21 Aug 2025 16:13:34 +0000

Date Added:

August 21, 2025

Journal/Publication:

The New England Journal of Medicine

Publication Date:

July 30, 2025

Issue:

Volume:

393

URL:

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Video

DOI (1):

10.1056/NEJMp2414535

Keywords

Uterine Cervical Neoplasms

Papillomavirus Vaccines

MeSH

Papillomavirus Vaccines

This is a 13 ½ minute audio-review of the link between HPV and various cancers and current recommendations regarding HPV immunization. James W. Mold, MD, MPH

Free full text

View

In this Double Take video from the New England Journal of Medicine, Dr. Julie Barzilay discusses the connection between certain strains of human papillomavirus (HPV) and cancer, as well as the evidence to support the safety and efficacy of the HPV vaccine in reducing the risk of cervical neoplasia. Strategies for discussing the HPV vaccine with patients and families are also reviewed.

Author/s:

Julie R. Barzilay, Sarah Feldman, Alison E. Burke, Emily Ling, Scott Williams, Caren G. Solomon

Cervical Cancer

Alex Haga — Wed, 08 Jan 2025 14:37:18 +0000

Date Added:

January 8, 2025

Journal/Publication:

New England Journal of Medicine

Publication Date:

January 1, 2025

Issue:

Volume:

392

Pages:

56-71

URL:

Cervical Cancer

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1056/NEJMra2404457

Keywords

cervical cancer

PMID (1):

39752299

MeSH

Cervical Cancer Screening

A review of current knowledge regarding cervical cancer. James W. Mold, MD, MPH

Free full text

View

Cervical cancer is preventable through vaccination and treatment of dysplasia identified on screening (cytologic screening, DNA testing for high-risk human papillomavirus subtypes, or both).
Early-stage cervical cancer is treated with open radical hysterectomy and pelvic lymphadenectomy; small lesions can be treated with extrafascial hysterectomy or more conservative fertility-preserving operations.
Locally advanced cervical cancer is treated with chemoradiation therapy plus brachytherapy; incorporation of immunotherapy for International Federation of Gynecology and Obstetrics (FIGO) stage III through IVA disease is associated with a survival benefit.
Isolated, centrally recurrent cervical cancer may be managed by means of pelvic exenteration with urinary diversion; however, owing to an increased incidence of distant or concomitant pelvic and extrapelvic relapse after widespread adoption of chemoradiation for locally advanced disease, fewer patients are candidates for this operation than in previous years.
Patients with newly diagnosed recurrent or metastatic disease may benefit from chemotherapy plus immunotherapy, with or without bevacizumab.
Antibody–drug conjugates may be an option for patients with disease progression after treatment with chemotherapy plus immunotherapy.

Author/s:

Krishnansu S Tewari

Cervical Cancer Screening

Erin Blanchette — Mon, 13 Nov 2023 16:19:48 +0000

Date Added:

November 14, 2023

Journal/Publication:

JAMA

Publisher:

American Medical Association

Publication Date:

October 27, 2023

URL:

Type:

Patient Education Materials

Format:

Article

DOI (1):

10.1001/jama.2023.21987

Keywords

PMID (1):

37889510

MeSH

Cervix Uteri

Papanicolaou Test

Patient education regarding cervical cancer screening. James W. Mold, MD, MPH

Free full text

View

This JAMA Patient Page discusses screening for cervical cancer, including who should be screened, recommendations for handling positive results, and the prevention of cervical cancer.

Author/s:

Rebecca A. Voelker

Cervical cancer screening guideline for individuals at average risk

Bethie Seay — Sun, 14 Nov 2021 06:00:00 +0000

Date Added:

November 14, 2021

Journal/Publication:

JAMA

Publication Date:

November 12, 2021

Type:

Meta-analyses, Reviews, and Guidelines

DOI (1):

10.1001/jama.2021.13448

MeSH

female

Adult

aged

Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.

American Cancer Society

The American Cancer Society’s most recent recommendations regarding cervical cancer screening.

View

Major recommendations

Begin screening at age 25 years regardless of sexual history or HPV vaccination status (strong recommendation)

Primary HPV testing every 5 years through age 65 years (strong recommendation)

If primary HPV testing is not available use cotesting (HPV+ cytology) every 5 years or every 3 years if cytology only (strong recommendation)

Discontinue screening at age 65 years if no history of cervical intraepithelial neoplasia grade 2 or more severe diagnosis in last 25 years and adequate negative prior screening in last 10 years (qualified recommendation)

Author/s:

Chor, J., Davis, A. M., Rusiecki, J. M.

Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.

Tracy Ashby — Tue, 04 Sep 2018 05:00:00 +0000

Date Added:

November 1, 2018

Journal/Publication:

JAMA

Publisher:

American Medical Association

Publication Date:

August 6, 2018

Issue:

Volume:

320

Pages:

674-686

URL:

Type:

Clinical Research Results, Public Health Announcements

Format:

Article

DOI (1):

10.1001/jama.2018.10897

Keywords

cervical cancer

screening

PMID (1):

30140884

MeSH